FIELD: chemistry; medicine.
SUBSTANCE: possibility of application in diagnostics of prostate gland cancer, and in differential diagnostics between prostate gland cancer and benign hyperplasia. Marker of prostate gland cancer consists of protein with molecular weight 28.5 kDa and visible isoelectric point 6.92, isolated from tumor tissue of prostate gland. Isolated marker protein includes peptides MPADLPSLAADFVESK; DVFLGMFLYEYAR; VFDEFKPLVEEPQNLIK; FQNALLVR; VPQVSTPTLVEVSR and AVMDDFAAFVEKCCK.
EFFECT: increase of accuracy of prostate gland cancer diagnostics.
2 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2012 |
|
RU2521389C2 |
| METHOD FOR DIAGNOSTICS OF PROSTATE ONCOLOGICAL DISEASES | 2007 |
|
RU2348042C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR BENIGN PROSTATE HYPERPLASIA AND PROSTATE CANCER | 2011 |
|
RU2464569C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2011 |
|
RU2469333C1 |
| DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2011 |
|
RU2464574C1 |
| METHOD FOR PREDICTION OF RISK OF BIOCHEMICAL RECURRENT IN PROSTATE CANCER PATIENTS AFTER RADIATION AND HORMONE THERAPY | 2015 |
|
RU2605838C1 |
| METHOD FOR PREDICTION OF AGGRESSIVE FORMS OF PROSTATE CANCER IN PATIENTS OF INTERMEDIATE AND HIGH RISK GROUP | 2021 |
|
RU2768477C1 |
| METHOD FOR SETTING DIFFERENTIAL DIAGNOSIS OF BENIGN HYPERPLASIA AND CANCER OF THE PROSTATE | 1999 |
|
RU2151397C1 |
| METHOD FOR DETECTING PATIENTS WITH HIGH RISK OF DEVELOPING PROSTATE CANCER | 2019 |
|
RU2740382C1 |
| METHOD FOR PROSTATE CANCER DIFFERENTIAL DIAGNOSIS BASED ON PLASMA MICRORNAS ANALYSIS | 2016 |
|
RU2618409C1 |
